Actinium Pharmaceuticals, Inc. (Delaware)
As of Oct 22, 2026, Actinium Pharmaceuticals, Inc. (Delaware) is in Stage 2, the uptrend phase, now in its first week (since Oct 20, 2026). It closed at $1.60, 5.3% below its 52-week high and above its 200-day average, which is falling.
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is ATNM early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ATNM among Biotechnology161st of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …161 | ATNM | Stage 2 · wk 1 | 60 | +35.6% |
Actinium Pharmaceuticals, Inc. (Delaware): quick answers
What stage is Actinium Pharmaceuticals, Inc. (Delaware) in?
As of Oct 22, 2026, Actinium Pharmaceuticals, Inc. (Delaware) (ATNM) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 20, 2026 and is in its first week there. What the four stages mean
Is Actinium Pharmaceuticals, Inc. (Delaware) in an uptrend?
Yes. Actinium Pharmaceuticals, Inc. (Delaware) is in a Stage 2 uptrend. It trades 43.1% above its 200-day average, which is falling.
How far is Actinium Pharmaceuticals, Inc. (Delaware) from its 52-week high?
Actinium Pharmaceuticals, Inc. (Delaware) closed at $1.60 on Oct 22, 2026, 5.3% below its 52-week high of $1.69. Its 52-week low is $0.75.
How has Actinium Pharmaceuticals, Inc. (Delaware) performed over the past year?
As of Oct 22, 2026, Actinium Pharmaceuticals, Inc. (Delaware) is up 6.0% over the past year and up 16.8% so far in 2026.
Which sector and industry is Actinium Pharmaceuticals, Inc. (Delaware) in?
Actinium Pharmaceuticals, Inc. (Delaware) is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.